350.
Haruka Maeda, Nobuo Saito, etc.,
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS), 2022.04.19,
https://academic.oup.com/cid/article/75/11/1971/6570603 .
Although high vaccine effectiveness of mRNA COVID-19 vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, and found mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July–September 2021, when the Delta variant was dominant nationwide.
349.
Amihai Rottenstreich, Olesya Vorontsov, etc.,
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination, 2022.05.24,
https://academic.oup.com/cid/article/75/11/2023/6590984 .
We evaluated the neutralization efficiency against SARS-CoV-2 Omicron variant in maternal and cord blood sera after antenatal BNT162b2 vaccination. Neutralizing antibodies against Omicron were lacking at the time of delivery after 2-dose vaccination. A third booster dose was essential in building neutralizing antibody capacity against Omicron among mothers and neonates.
348.
Char Leung, Li Su, etc.,
Better healthcare can reduce the risk of COVID-19 in-hospital post-partum maternal death: evidence from Brazil, 2022.08.10,
https://academic.oup.com/ije/article/51/6/1733/6659906 .
COVID-19 in post-partum women is commonly overlooked. Post-partum women had almost twice the odds of COVID-19 in-hospital mortality compared with pregnant patients. Part of the mortality risk is preventable through quality healthcare such as the presence of an obstetric centre in the hospital, non-profit private healthcare and hospitals in urban areas.
347.
Kasper P Kepp, Jonas Björk, etc.,
Estimates of excess mortality for the five Nordic countries during the COVID-19 pandemic 2020−2021, 2022.11.04,
https://academic.oup.com/ije/article/51/6/1722/6798817 .
Excess mortality during the COVID-19 pandemic is of major scientific and political interest. Excess mortality during the COVID-19 pandemic is of major scientific and political interest. We show using back-calculation of expected deaths from Nordic all-cause deaths that the Institute for Health Metrics and Evaluation model is a clear outlier in the compared estimates and likely substantially overestimates excess mortality of Finland and Denmark, and probably Sweden.
346.
Neftali Eduardo Antonio-Villa, Omar Yaxmehen Bello-Chavolla, etc.,
Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico, 2022.09.29,
https://academic.oup.com/ije/article/51/6/1711/6731613 .
Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Non-COVID-19 causes of death, largely chronic cardiometabolic conditions, comprised up to one-fifth of excess deaths in Mexico during 2020.
345.
Jessie Zeng, Joshua Szanyi, etc.,
Effectiveness of fourth dose of COVID-19 vaccine against the Omicron variant compared with no vaccination, 2022.12.16,
https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyac231/6917096?searchresult=1 .
Waning COVID-19 vaccine effectiveness (VE) and the capacity of the Omicron SARS-CoV-2 variant to evade pre-existing immunity have been major impediments to COVID-19 control efforts worldwide. In response, several countries have rolled out fourth-dose COVID-19 vaccination programmes. We find that a fourth dose of the BNT162b2 vaccine appears to restore, if not boost even more, the protection conferred by a third dose at an equivalent time post-vaccination.
344.
Alexandros Mitropoulos, Simon Goodwill, etc.,
The relationship between physical activity and severity of COVID-19 symptoms in non-hospitalized individuals, 2022.07.22,
https://academic.oup.com/eurpub/article/32/5/794/6648347 .
Our findings did not present an association between PA levels and mild-to-moderate COVID-19 symptoms. However, all participants exceeded the lower limit of the World Health Organization recommended, adult PA dose. This might explain the lack of PA effect, on mild-to-moderate symptoms post-COVID-19 infection.
343.
Thara Rangaswamy, Sandeep Grover, etc.,
How Did the Mental Health Care System in India Respond to COVID 19 Pandemic?, 2022.10.18,
https://academic.oup.com/schizbullopen/article/3/1/sgac043/6762545?searchresult=1 .
This paper examines the various strategies in response to COVID-19 adopted by the Government of India, the health departments of the individual states, and other private players such as on-government organizations and the civil society. Based on our experience with COVID-19, we urge a strong call for action, in terms of strengthening the primary care facilities and increasing the manpower resources to deliver mental health care.
342.
Sandra Rajme-López, Bernardo A Martinez-Guerra, etc.,
Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study, 2022.10.06,
https://academic.oup.com/ofid/article/9/10/ofac502/6750022 .
Early outpatient treatment with remdesivir significantly reduces hospitalization or death by 84% in high-risk, majority immunosuppressed patients with Omicron variant COVID-19.
341.
M Premikha, Calvin J Chiew, etc.,
Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore, 2022.06.06,
https://academic.oup.com/cid/article/75/8/1442/6567428 .
Compared with individuals vaccinated with Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaVac and Sinopharm were 2.37 (95% CI, 2.29–2.46) and 1.62 (95% CI, 1.43–1.85) times more likely to be infected with coronavirus disease 19, respectively, while individuals vaccinated with Moderna were 0.42 (95% CI, 0.25–0.70) times less likely to develop severe disease.
Chinese Society of International Law, in association with Chinese Institute of International Law at China Foreign Affairs University, and National Center for Foreign-related Rule of Law Research at China Foreign Affairs University
Contact: secretary@bigghgg.cn